eli lilly tirzepatide fda approval New Medication approved by the for Chronic Weight Management! FDA approves blockbuster Eli Lilly

This novel anti-obesity and weight loss-promoting drug is the first twincretin, composed of GLP-1 receptor (GLP1-R) and GIP-receptor (GIP-R) agonists

It does not interact with cytochrome P450 enzymes in the liver, which means fewer drug interaction concerns than many other medications

Option 4: Apple with unsweetened, natural nut butter

It carries CAS number 137525-51-0, the molecular formula C62H98N16O22, and a molecular weight of 1419.56 g/mol, and it is catalogued in PubChem as compound 9941957

Tirzepatide, on the other hand, works on two hormone receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide)